120 related articles for article (PubMed ID: 11261939)
1. Serine proteases and brain damage - contribution of the urokinase- plasminogen activator system.
Schwab JM; Meyermann R; Schluesener HJ
Trends Neurosci; 2001 Jan; 24(1):8-9. PubMed ID: 11261939
[No Abstract] [Full Text] [Related]
2. Multiple pathways of cell invasion are regulated by multiple families of serine proteases.
Del Rosso M; Fibbi G; Pucci M; D'Alessio S; Del Rosso A; Magnelli L; Chiarugi V
Clin Exp Metastasis; 2002; 19(3):193-207. PubMed ID: 12067200
[TBL] [Abstract][Full Text] [Related]
3. Urokinase-type plasminogen activator and its receptor in bladder cancer.
Hasui Y; Osada Y
J Natl Cancer Inst; 1997 May; 89(10):678-9. PubMed ID: 9168177
[No Abstract] [Full Text] [Related]
4. Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells.
Sprague LD; Tomaso H; Mengele K; Schilling D; Bayer C; Stadler P; Schmitt M; Molls M
Oncol Rep; 2007 May; 17(5):1259-68. PubMed ID: 17390074
[TBL] [Abstract][Full Text] [Related]
5. Expression pattern of the urokinase-plasminogen activator system in rat DS-sarcoma: role of oxygenation status and tumour size.
Weinmann M; Thews O; Schroeder T; Vaupel P
Br J Cancer; 2002 Apr; 86(8):1355-61. PubMed ID: 11953898
[TBL] [Abstract][Full Text] [Related]
6. Unexpected role of plasminogen activator inhibitor 1 in cell adhesion and detachment.
Czekay RP; Loskutoff DJ
Exp Biol Med (Maywood); 2004 Dec; 229(11):1090-6. PubMed ID: 15564434
[TBL] [Abstract][Full Text] [Related]
7. Regulation and interactions in the activation of cell-associated plasminogen.
Myöhänen H; Vaheri A
Cell Mol Life Sci; 2004 Nov; 61(22):2840-58. PubMed ID: 15558213
[TBL] [Abstract][Full Text] [Related]
8. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer.
Duffy MJ; Duggan C
Clin Biochem; 2004 Jul; 37(7):541-8. PubMed ID: 15234235
[TBL] [Abstract][Full Text] [Related]
9. Methods to analyze the effects of the urokinase system on cancer cell adhesion, proliferation, migration, and signal transduction events.
Reuning U; Schmitt M; Luber B; Beck V; Magdolen V
Methods Mol Med; 2006; 120():427-40. PubMed ID: 16491616
[TBL] [Abstract][Full Text] [Related]
10. Sphingosine-1-phosphate and interleukin-1 independently regulate plasminogen activator inhibitor-1 and urokinase-type plasminogen activator receptor expression in glioblastoma cells: implications for invasiveness.
Bryan L; Paugh BS; Kapitonov D; Wilczynska KM; Alvarez SM; Singh SK; Milstien S; Spiegel S; Kordula T
Mol Cancer Res; 2008 Sep; 6(9):1469-77. PubMed ID: 18819934
[TBL] [Abstract][Full Text] [Related]
11. Molecular and functional interdependence of the urokinase-type plasminogen activator system with integrins.
Reuning U; Magdolen V; Hapke S; Schmitt M
Biol Chem; 2003 Aug; 384(8):1119-31. PubMed ID: 12974381
[TBL] [Abstract][Full Text] [Related]
12. [Expression of urokinase plasminogen activator, its receptor and plasminogen activator inhibitor type 1 in different types of atherosclerotic lesion in human aorta].
Solomatina MA; Plekhanova OS; Il'inskaia OP; Kalinina NI; Mikhaĭlova EV; Tsokolaeva ZI; Tararak EM; Naumov VG; Parfenova EV
Tsitologiia; 2004; 46(4):352-60. PubMed ID: 15346794
[TBL] [Abstract][Full Text] [Related]
13. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.
Leonardi A; Brun P; Sartori MT; Cortivo R; Dedominicis C; Saggiorato G; Abatangelo G; Secchi AG
Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1364-70. PubMed ID: 15790903
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and alpha(2)-macroglobulin receptor in human breast carcinomas.
Christensen L; Wiborg Simonsen AC; Heegaard CW; Moestrup SK; Andersen JA; Andreasen PA
Int J Cancer; 1996 May; 66(4):441-52. PubMed ID: 8635858
[TBL] [Abstract][Full Text] [Related]
15. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
Tecimer C; Doering DL; Goldsmith LJ; Meyer JS; Abdulhay G; Wittliff JL
Gynecol Oncol; 2001 Jan; 80(1):48-55. PubMed ID: 11136569
[TBL] [Abstract][Full Text] [Related]
16. Tumour cell thrombospondin-1 regulates tumour cell adhesion and invasion through the urokinase plasminogen activator receptor.
Albo D; Rothman VL; Roberts DD; Tuszynski GP
Br J Cancer; 2000 Aug; 83(3):298-306. PubMed ID: 10917542
[TBL] [Abstract][Full Text] [Related]
17. Endostatin-induced modulation of plasminogen activation with concomitant loss of focal adhesions and actin stress fibers in cultured human endothelial cells.
Wickström SA; Veikkola T; Rehn M; Pihlajaniemi T; Alitalo K; Keski-Oja J
Cancer Res; 2001 Sep; 61(17):6511-6. PubMed ID: 11522648
[TBL] [Abstract][Full Text] [Related]
18. Prognostic relevance of urokinase type plasminogen activator, its receptor and inhibitors in chondrosarcoma.
Morii T; Yabe H; Morioka H; Yamada R; Nakagawa T; Toyama Y
Anticancer Res; 2000; 20(5A):3031-6. PubMed ID: 11062719
[TBL] [Abstract][Full Text] [Related]
19. Effects of hormones on uPA, PAI-1 and suPAR from cultured endometrial and ovarian endometriotic stromal cells.
Guan YM; Carlberg M; Bruse C; Carlström K; Bergqvist A
Acta Obstet Gynecol Scand; 2002 May; 81(5):389-97. PubMed ID: 12027810
[TBL] [Abstract][Full Text] [Related]
20. The role of the pericellular fibrinolytic system in angiogenesis.
Fukao H; Ueshima S; Okada K; Matsuo O
Jpn J Physiol; 1997 Apr; 47(2):161-71. PubMed ID: 9201545
[No Abstract] [Full Text] [Related]
[Next] [New Search]